60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns “Sell (E+)” Rating from Weiss Ratings

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “sell (e+)” rating reiterated by analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

Other research analysts have also issued research reports about the company. Ascendiant Capital Markets cut their price target on 60 Degrees Pharmaceuticals from $7.00 to $3.00 and set a “buy” rating on the stock in a report on Wednesday, September 3rd. Wall Street Zen lowered 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, June 14th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $3.00.

60 Degrees Pharmaceuticals Trading Down 2.1%

NASDAQ:SXTP opened at $1.37 on Friday. 60 Degrees Pharmaceuticals has a 12 month low of $1.22 and a 12 month high of $12.45. The stock has a market capitalization of $5.62 million, a price-to-earnings ratio of -0.03 and a beta of 2.72. The firm has a fifty day simple moving average of $1.47 and a two-hundred day simple moving average of $2.04.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of ($1.24) by ($0.01). The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.32 million. Equities analysts predict that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current fiscal year.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.